Torsten Rüdiger Goesch

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.